Loading...
Although the next-generation regimens for hepatitis C virus (HCV) are effective, currently, the standard approved regimen for patients receiving hemodialysis is still peginterferon plus low-dose ribavirin (200 mg/day). The addition of low-dose ribavirin was approved by the FDA in August 2011. However, that approval was based on small studies that were very heterogeneous with regard to treatments, HCV genotypes, and endpoints. Therefore, the efficacy and safety of combination therapy compared with monotherapy in this population is unclear.
In the current open-label, randomized, controlled trial, 205 treatment-naive patients with genotype 1 HCV infection receiving hemodialysis were randomized to receive either peginterferon alone (135 µg weekl…